MetaVia Presents Positive Phase 1 and Preclinical Data for Dual Agonist DA-1726 at ObesityWeek® 2025

DA-1726 demonstrates favorable safety, dose-proportional pharmacokinetics, and meaningful weight loss in Phase 1 trial; preclinical data show superior lipid-lowering efficacy compared with pemvidutide.

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company advancing therapies for cardiometabolic diseases, announced new Phase 1 and preclinical data for DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting both the GLP-1 receptor (GLP1R) and glucagon receptor (GCGR). The data were presented in two posters at ObesityWeek® 2025, held November 4–7 in Atlanta, Georgia.

Phase 1 Study Highlights: Promising Efficacy and Safety Profile

The Phase 1 study demonstrated favorable safety, tolerability, and a pharmacokinetic (PK) profile supporting once-weekly dosing. Participants treated with DA-1726 showed clinically meaningful reductions in body weight and waist circumference after four weeks of treatment.

• At the 32 mg dose, participants experienced up to a 6.3% reduction in body weight from baseline, with an average loss of 4.3% at Day 26.
• Waist circumference decreased by as much as 3.9 inches, with effects persisting for two weeks after dosing stopped.
• PK analysis revealed linear, dose-proportional exposure and an approximately 80-hour mean half-life, confirming once-weekly dosing feasibility.
• No serious adverse events (SAEs), discontinuations, or dose-limiting toxicities were reported. Gastrointestinal (GI) events were mild and transient, and no significant cardiovascular changes were observed.

Study Design: The randomized, double-blind, placebo-controlled Phase 1 trial evaluated single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults (BMI 30–45 kg/m²). Each cohort included nine participants randomized 6:3 to receive four once-weekly subcutaneous doses of DA-1726 or placebo.

Primary objectives assessed safety and tolerability, while secondary and exploratory endpoints evaluated pharmacokinetics, pharmacodynamics, and metabolic parameters such as body weight, BMI, lipid profile, and waist circumference.

The study has been extended to include a 48 mg dose for 8 weeks to further assess longer-term efficacy and the maximum tolerated dose. Results from this cohort are expected later this year.

“These results reinforce DA-1726’s potential as a differentiated dual agonist for obesity treatment,” said Hyung Heon Kim, Chief Executive Officer of MetaVia. “The combination of clean cardiovascular findings, early weight loss without titration, and consistent once-weekly dosing is highly encouraging.”

Preclinical Data: Strong Weight and Lipid-Lowering Effects

In diet-induced obesity (DIO) mouse models, DA-1726 demonstrated comparable weight-loss efficacy to pemvidutide while achieving superior lipid-lowering outcomes, including greater reductions in total cholesterol (T-CHO) and low-density lipoprotein cholesterol (LDL-C).

• Compared with tirzepatide, DA-1726 produced greater weight loss despite similar food intake, driven by enhanced energy expenditure unrelated to increased physical activity.
• When compared with pemvidutide, DA-1726 achieved similar reductions in fat mass while preserving lean body mass, and demonstrated stronger improvements in lipid metabolism, including reductions in triglycerides.

“DA-1726’s differentiated metabolic profile suggests potential for broader and more durable benefits across obesity and related metabolic disorders,” said Tae-Hyoung Kim, M.S., Lead Research Scientist at Dong-A ST.

Poster Presentation Details

Poster 1:

• Title: Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodulin Analogue in a Phase 1 Study
• Presenter: Chris Fang, M.D., Consulting Chief Medical Officer, MetaVia
• Poster Number: P-209
• Date: Tuesday, November 4, 2025
• Time: 7:30–8:30 p.m. ET
• Location: Exhibit Hall A1

Poster 2:

• Title: DA-1726, an Oxyntomodulin Analogue: A Promising Therapy for Obesity and Related Metabolic Disorders
• Presenter: Tae-Hyoung Kim, M.S., Lead Research Scientist, Dong-A ST
• Poster Number: P-154
• Date: Tuesday, November 4, 2025
• Time: 7:30–8:30 p.m. ET
• Location: Exhibit Hall A1

Copies of the posters are available in the Posters section of the MetaVia website.

About DA-1726

DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a dual GLP1R/GCGR agonist designed for once-weekly subcutaneous administration. The molecule promotes weight loss by reducing appetite and increasing energy expenditure, while also improving lipid metabolism.

In preclinical models, DA-1726 achieved:

• Greater weight reduction than semaglutide (Wegovy®)
• Comparable efficacy to tirzepatide (Zepbound®) and survodutide, while preserving lean mass
• Superior lipid-lowering effects relative to survodutide

The compound is being developed for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).

About MetaVia

MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company’s pipeline includes:

• DA-1726, a dual GLP1R/GCGR agonist for obesity and MASH, currently in Phase 1 development.
• Vanoglipel (DA-1241), a GPR119 agonist that promotes the release of key gut peptides (GLP-1, GIP, PYY) and has shown improvements in liver inflammation, lipid metabolism, and glucose control in preclinical and clinical studies.

MetaVia aims to develop best-in-class therapies leveraging multi-receptor biology to improve metabolic, hepatic, and cardiovascular health in patients worldwide.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!